Naloxone-induced pulmonary oedema was first reported in 1977. It is a rare but potentially fatal reaction to a drug once regarded as totally safe. We present two cases of possible naloxone-induced pulmonary oedema which illustrate some of the problems in diagnosis. We would also like to suggest that phentolamine might be a useful adjunct to the conventional management of these reactions.
CASE REPORT I An eighteen-year-old, 82-kg male presented to a local hospital with acute appendicitis. He was previously fit and had no known allergies. He was moderately dehydrated, but otherwise well. In the eight hours prior to surgery he received one litre of normal saline and one litre of 5% dextrose. He was premedicated with pethidine 100 mg. Following pre-oxygenation, a rapid sequence induction was OF performed with thiopentone 500 mg, suxamethonium 100 mg and cricoid pressure. Intubation was easy. Anaesthesia was maintained with halothane, alcuronium 20 mg and pethidine 100 mg. Monitoring included ECG, indirect blood pressure measurement and pulse oximetry. The procedure lasted 1.5 hours during which a gangrenous appendix was removed. Hartmann's solution 500 ml and cefoxitin 2 g were given intraoperatively. Anaesthesia was uneventful and neuromuscular blockade reversed with neostigmine 2.5 mg and atropine 1.2 mg. Respiratory effort however was poor and a further dose of neostigmine 2. 5 mg and atropine 0.6 mg were given empirically. Since there was little improvement in respiratory effort and the pupils pinpoint, naloxone 0.4 mg was given as a bolus. Shortly afterwards the patient was extubated on his side when his breathing and conscious state was deemed adequate. Within a minute, however, he developed marked respiratory distress, which at the time was thought to be due to laryngospasm, and he became cyanosed. The oxygen saturation continued to fall despite 100% oxygen and CP AP via a mask. The patient became profoundly hypoxic and rapidly lost consciousness. Suxamethonium 100 mg was administered, cricoid pressure applied and the patient re-intubated in the supine position. There was no evidence of aspiration. With 100% oxygen, PEEP and IPPV the Sa02 improved to 90% and copious blood stained frothy 'oedema' fluid was aspirated from the endotracheal tube. Haemodynamically, however, the patient remained stable with a mean pressure of 80 mmHg. Frusemide 20 mg, hydrocortisone 200 mg and midazolam 10 mg were given. A chest X-ray at the time revealed widespread fluffy shadowing. A Swan-Ganz catheter was not available for insertion. All other investigations including an ECG were normal.
The patient was ventilated for two hours and transferred to an intensive care unit where he was managed with further doses of frusemide. He had a brisk diuresis and improved rapidly. Within 24 hours he had a clear chest X-ray, normal blood gases and was transferred to the ward.
CASE REPORT 2
A 69-year-old, 74-kg male presented for a diagnostic fibreoptic bronchoscopy for investigation of a left hilar mass. He had severe chronic obstructive airways disease, cor pulomonale and ischaemic heart disease. He was taking anti-anginal medication, diuretics, bronchodilators, digoxin, aminophylline and prednisolone. He had no known allergies. His ECG showed P-pulmonale, non-specific T -wave flattening and right axis deviation and his chest X-ray revealed a left hilar opacity, clear fields and prominent pulmonary vessels. He had a compensated respiratory acidosis with a PaC02 of 51 mmHg and an Sa02 of 67% on air. He was dyspnoeic on minimal exertion.
The oropharynx was anaesthetised with 3 ml of 4% lignocaine spray and a cri co-thyroid puncture performed with a further 3 ml4% lignocaine. A size 3 laryngeal mask airway (LMA) was easily inserted and an uneventful fibre-optic bronchoscopy performed. Monitoring included an ECG, pulse oximetry and indirect blood pressure. During the bronchoscopy the patient was given propofol30 mg and fentanyl 50 micrograms for sedation and remained haemodynamically stable and with an Sa02 of 97% on approximately 70% oxygen.
At the end of the procedure, however, the patient was too heavily sedated for removal of the LMA and naloxone 0.15 mg was given. Since there was no improvement after three minutes, the dose was repeated. On this occasion he became fully responsive, his breathing vigorous and the LMA was removed. However, within a minute he became restless, needed to sit up and his breathing became increasingly difficult. After a short period of ventilation with a mask, he was intubated. His Anaesthesia and Intensive Care. Vol. 19. No. 4. November. /99/ airway pressures were high with widespread rhonchi and he was bradycardic and hypotensive. He was given atropine 0.6 mg and ventilated on 100% oxygen and 1.5% isoflurane. His blood pressure and pulse improved slightly, but the bronchospasm persisted with an Sa02 of 57%. At this point it was decided to try alpha-blockade and phentolamine 1 mg was given IV. Within thirty seconds airway pressures returned to normal, the bronchospasm disappeared and the Sa02 improved to 93%. He became transiently tachycardic, but his pulse rapidly reverted to normal and he became normotensive. The isoflurane was discontinued. This improvement lasted for six mintues during which time auscultation revealed normal air entry and no rhonchi. He deteriorated again with rhonchi and increasing airway pressure. This responded promptly and completely to a further 1 mg phentolamine. The patient deteriorated twice more during the next thirty minutes and on each occasion the response to phentolamine 1 mg was similar. He was transferred to ICU and an infusion of phentolamine was established at 30 mg/hr. Over the next three hours the respiratory problem returned at each attempt to wean the phentolamine, but by the fourth hour the infusion was successfully discontinued. He was extubated one hour after admission to ICU when fully conscious. Unfortunately no chest X-ray was taken at this time, however, his blood gases, ECG and electrolytes were similar to preoperative values. He was returned to the ward eighteen hours later. Over the next two days there was no rise in cardiac enzymes or new change in the ECG, suggesting that myocardial infarction had not occurred.
DISCUSSION
The cardiovascular complications of naloxone administration have been widely documented and include hypertension, l tachycardia,2 ventricular arrhythmias, 3 cardiac arrest 4 and acute pulmonary oedema. 5 -8 These reactions are uncommon, but can occur in healthy patients,7-9 are occasionally lethal 4 and can occur with small doses. 6 It has been proposed that naloxone has the following actions on the cardiovascular system: (a) a centrally mediated increase in sympathetic tone, (b) a decrease in parasympathetic output, (c) peripheral antagonism of opioid peptides released in shock states and (d) stabilisation oflysosomes. lO It has been suggested that the pathogenesis of naloxone-induced pulmonary oedema is similar to neurogenic pulmonary oedema, i.e. that of a centrally mediated massive catecholamine response leading to a dramatic shift of blood volume into the pulmonary vascular bed. Pronounced increases in pulmonary vascular pressures and blood volume then produce pulmonary oedema because of the hydrostatic effect of increased pulmonary capillary pressure. In addition this process damages pulmonary blood vessels and the patient is left with abnormally high pulmonary capillary permeability so that pulmonary oedema can persist long after the initial insult. 7, 11 Acute pulmonary oedema can also be produced by upper airway obstruction. 12 Often both upper airway obstruction and naloxone administration are features of a patient presenting with acute pulmonary oedema associated with anaesthesia and it is difficult to diagnose the precipitating cause. 8 ,13 Case 1 is a good example of this. The diagnosis of acute pulmonary oedema in a fit young man is not in doubt, but the cause could either be airway obstruction or a reaction to naloxone, though the latter appears more likely given the transient nature of the respiratory distress and the timing of events.
The aetiology of acute respiratory failure is less clear in Case 2 because of associated cardiorespiratory disease, the nature of the procedure and the lack of radiological evidence. The time course of events, however, again suggests that naloxone was the most likely cause of respiratory failure. The predominant clinical feature in this case was severe rapidly reversible bronchospasm which we believe was secondary to acute pulmonary oedema, though a direct action on bronchial smooth muscle cannot be excluded.
Phentolamine is a competitive alpha-blocking drug that has a similar affinity for alpha-l and alpha-2 receptors. It also blocks 5-RT receptors and causes mast cells to release histamine. It has no effect on bronchial smooth muscle when given alone, is of doubtful value in the treatment of pulmonary hypertension and is mainly used to control hypertension in phaeochromocytoma. 14 ,15 Its use in the treatment of sympathetic overactivity is well described in the management of Irukandji syndrome. [16] [17] [18] This syndrome is caused by envenomation by the jellyfish Carukia bamesi. Many of the features of this syndrome, including pulmonary oedema, can be explained by massive catecholamine release, though the precise pathophysiology awaits elucidation.
We would like to suggest that the pathophysiology of pulmonary oedema in Irukandji syndrome and naloxone-induced pulmonary oedema may be similar. Given that the cause of acute respiratory failure in Case 2 was naloxone-induced pulmonary oedema, the brisk and repeated responses to phentolamine would support the above hypothesis.
Despite the circumstantial nature of the evidence we feel that alpha-blockade may be worthwhile in the management of naloxone-induced pulmonary oedema.
